Rao Sunil V, Ohman E Magnus, Granger Christopher B, Armstrong Paul W, Gibler W Brian, Christenson Robert H, Hasselblad Vic, Stebbins Amanda, McNulty Steven, Newby L Kristin
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA.
Am J Cardiol. 2003 Apr 15;91(8):936-40. doi: 10.1016/s0002-9149(03)00107-3.
The risk of death or recurrent myocardial infarction (MI) in patients with chest pain and baseline isolated troponin elevation is unclear. To determine the early and short-term risk of death or MI associated with isolated troponin elevation across a spectrum of chest pain syndromes, we used baseline creatine kinase (CK)-MB and troponin data from the Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON) B troponin substudy, the Global Utilization of Strategies To Open Occluded Coronary Arteries (GUSTO) IIa troponin substudy, and the Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) study. Patients were grouped into 1 of 4 categories based on marker status (troponin-positive/CK-MB-positive, troponin-positive/CK-MB-negative, troponin-negative/CK-MB-positive, or troponin-negative/CK-MB-negative). The adjusted odds of death or MI occurring at 24 hours and 30 days was assessed by baseline marker status using multivariable logistic regression, with the group negative for both markers used as the reference. Patients who were positive for both markers had the highest odds of the 24-hour and 30-day end point. The adjusted odds of the 30-day end point for patients with isolated troponin elevation were 1.3 (95% confidence interval 0.7 to 2.3) and 4.8 (95% confidence interval 1.4 to 16.0) for high- and low-risk patients, respectively. The risk for 24-hour and 30-day death or MI with isolated positive CK-MB results was lower than with isolated positive troponin results, and it was not significantly greater than if the 2 markers were negative. For patients with high- and low-risk chest pain, baseline troponin elevation without CK-MB elevation was associated with increased risk for early and short-term adverse outcomes. This suggests that these patients should be admitted to the hospital and monitored in either an intensive care or step-down unit.
胸痛且基线肌钙蛋白单独升高的患者发生死亡或复发性心肌梗死(MI)的风险尚不清楚。为了确定在一系列胸痛综合征中与肌钙蛋白单独升高相关的早期和短期死亡或MI风险,我们使用了来自全球组织网络中血小板IIb/IIIa拮抗剂降低急性冠状动脉综合征事件(PARAGON)B肌钙蛋白子研究、全球开放闭塞冠状动脉策略应用(GUSTO)IIa肌钙蛋白子研究以及肌酸激酶-MB、肌红蛋白和肌钙蛋白I胸痛评估(CHECKMATE)研究的基线肌酸激酶(CK)-MB和肌钙蛋白数据。根据标志物状态(肌钙蛋白阳性/CK-MB阳性、肌钙蛋白阳性/CK-MB阴性、肌钙蛋白阴性/CK-MB阳性或肌钙蛋白阴性/CK-MB阴性)将患者分为4类中的1类。使用多变量逻辑回归,以两种标志物均为阴性的组作为对照,通过基线标志物状态评估24小时和30天时发生死亡或MI的校正比值比。两种标志物均为阳性的患者在24小时和30天终点的比值比最高。肌钙蛋白单独升高的患者在30天终点的校正比值比,高危患者为1.3(95%置信区间0.7至2.3),低危患者为4.8(95%置信区间1.4至16.0)。CK-MB单独阳性结果的患者在24小时和30天发生死亡或MI的风险低于肌钙蛋白单独阳性结果的患者,且不比两种标志物均为阴性时显著更高。对于高危和低危胸痛患者,基线肌钙蛋白升高而无CK-MB升高与早期和短期不良结局风险增加相关。这表明这些患者应入院并在重症监护病房或降级病房进行监测。